The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The History of Treating Lupus with Hydroxychloroquine

The History of Treating Lupus with Hydroxychloroquine

June 15, 2020 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Study Impact

The paper attracted much interest and served as the focus of a plenary session at that year’s ACR/ARHP Annual Scientific Meeting. Due to its influence, physicians became much more likely to prescribe hydroxychloroquine over the long term. Sales of the drug, still under patent then, went up markedly after the paper’s release.

You Might Also Like
  • New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine
  • Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?
  • Diagnostic Imaging in Lupus Patient with Foot Pain: History
Explore This Issue
June 2020
Also By This Author
  • COVID-19 Vaccine Efficacy & Safety Discussed at Town Hall

Today, hydroxychloroquine is a staple treatment of lupus. In the absence of rare contraindications, most experts recommend lifelong treatment with hydroxychloroquine for all lupus patients, regardless of disease severity or additional therapies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The study demonstrated that hydroxychloroquine wasn’t just for active lupus, but had a major preventive role,” Dr. Petri says.

In addition to lupus, hydroxychloroquine is less frequently used to treat RA and certain other inflammatory rheumatologic diseases. The drug is also under consideration for new applications, such as heart disease, diabetes mellitus and certain cancers.8

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Since the initial study by the Canadian Hydroxychloroquine Study Group, researchers in other follow-up studies have confirmed the important role of hydroxychloroquine in preventing lupus disease flares. Scientists have also learned much about the drug’s multiple beneficial effects. Over the years, it has become evident that hydroxychloroquine does more than suppress mild disease, as was initially believed.

Explains Dr. Petri, “I’ve spent the past 34 years trying to build on what the Canadians showed back in 1991. We know now [hydroxychloroquine] helps improve survival; it reduces cardiovascular risk factors, thrombosis, renal damage, central nervous system lupus and more.”

A population-based, case-controlled study from 2019 demonstrated that mortality risk increased almost fourfold in people who had to stop taking their hydroxychloroquine.9 It is the only drug that has been demonstrated to improve the survival of lupus patients. Hydroxychloroquine also appears to be a safe and effective drug in pregnant patients, reducing flares during this time and decreasing the risk of cardiac neonatal lupus.6

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Continued Safety Concerns for Hydroxychloroquine

Although the potential impact of hydroxy­chloroquine is undeniable, its safety is again being questioned. For reasons that are unclear, the incidence of retinopathy appears to have been increasing in recent years. Dr. Petri notes that research has demonstrated that retinopathy from hydroxychloroquine is more common than previously thought. This is a major concern, because late retinopathy is not reversible, and no currently available therapies can treat it.8

Dr. Petri et al. recently published an article demonstrating that about 11% of lupus patients taking hydroxychloroquine will have to stop it after 16 years due to signs of early retinopathy.10 Dr. Petri explains this may be due to the greater sensitivity of newer ophthalmology screening tests for retinopathy, such as optical coherence tomography (OCT), which may be picking up milder retinopathy at a much earlier stage than was possible in the past.

“We are facing the fact that hydroxychloroquine is not going to be allowed in every single patient for their lifetime of lupus,” she says. “I’m always annoyed when I get a note from an ophthalmologist who tells me to start a substitute for hydroxychloroquine due to retinopathy. We do not have a substitute for it; we have nothing to replace it.”

She hopes this will serve as an impetus for the research community to find better or additional lupus therapies.

In 2016, the American Academy of Ophthalmology published guidelines for hydroxychloroquine patient monitoring, recommending OCT at baseline, five years thereafter and then every year following for patients without major risk factors for retinopathy.8

Questions also remain about optimal dosing of the drug. Higher doses have been associated with a greater risk of retinopathy. In terms of toxicity, recent guidelines from the American Academy of Ophthalmology recommend lowering the dosage from 6.5 mg/kg patient weight to less than 5.0 mg/kg.8

Dr. Petri responds, “The concern has been, if you reduce the dose, we’re going to reduce the efficacy.” At the 2019 ACR/ARP Annual Meeting, Dr. Petri presented data demonstrating that lowered blood levels of hydroxychloroquine did, in fact, increase the risk of thrombosis in lupus patients.11

Hydroxychloroquine blood levels may provide a way to find optimal efficacy with a lower risk of retinopathy. Dr. Petri explains, “Blood levels reflect how much the patient has taken over the past month, very similar to a hemoglobin A1c in diabetes; it’s really reflective of their adherence.” She believes these blood levels can help identify people who are taking more hydroxychloroquine than needed—people who could safely have their dose lowered.

Hydroxychloroquine blood levels are becoming more universally available. Dr. Petri explains that Exagen provides a commercial source, and labs like Quest Diagnostics also offer them. “Some other labs,” she notes, “have offered plasma levels, which aren’t as accurate. Hydroxychloroquine binds to red cells, so plasma grossly underestimates the actual exposure. This is a field in flux—using therapeutic blood monitoring to guide dosing of hydroxychloroquine, so that we do not give too little or too much.”

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Lost & Found, retinopathy, SLE Resource CenterIssue: June 2020

You Might Also Like:
  • New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine
  • Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?
  • Diagnostic Imaging in Lupus Patient with Foot Pain: History
  • Reflections on Living with Lupus, and on Treating It

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)